C-9NYQMorphoceuticals Inc
bioelectrome, multi-omics, AI
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-9NYQ
C-9NYQC-9NYQbioelectrome, multi-omics, AI
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Member Spotlight Archives - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link Align Summi
%PDF-1.4 %���� 287 0 obj > endobj 286 0 obj >stream PScript5.dll Version 5.2.2 2026-06-25T00:11:22-07:00 2022-11-09T07:24:31-08:00 2026-06-25T00:11:22-07:00 application/pdf Exploring The Behavior of Bioelectric Circuits using Evolution Heuristic Search Administrator Acrobat Distiller 8.1.0 (Windows) uuid:2568e1d1-1dd2-11b2-0a00-130927edca00 uuid:2568e1d5-1dd2-11b2-0a00-380000000000 endstream endobj 285 0 obj > endobj 12 0 obj > endobj 2 0 obj > endobj 56 0 obj > endobj 65 0 obj > endobj 66 0 obj > endobj 67 0 obj > endobj 68 0 obj > endobj 220 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/Image … {V8ͩ�k�� k���]�����}O����c��Jif�#. .�g� ��0buC��b�,ia"@=נtn�� ��@��_�-,��FUNdן��y��P�" �c?�g��f�ǭ5���Y��Y����M����/�����VQ0�����mYS��H� �\O�����(�m�������("?Y~m�K�U� �e7�� � �� ��h�R�\�K���HsK �n�KbCCL��###+��m��hKD� bGq+)�T^w��5��� ��a��1�Z_;��fy쒝�~���{��t���v���k�;dL(S�)��O�]��O��0�E���Vl5�n�7].�x�N�X�b�,�Kv�US�:���uIN�K=J���i x\�M���-���F��%t�զ �tjo_��;\w������YY ]kc 4��>���dɩ[��x���hu�1�(/�4�BCI�~�⺏�\�� �.l�g�7�Y��l!�{�[�I:�� �b?�� �#
#037: Jan 11th, 2022 - Longevity Marketcap Newsletter Longevity Marketcap Newsletter Subscribe Sign in #037: Jan 11th, 2022 - Longevity Marketcap Newsletter 2021 Industry Review. NewLimit. New Funds. Longevity Biotech Job Fair. Nathan S. Cheng Jan 11, 2022 6 Share Announcements Last Week(s) in Longevity Longevity Futures Capital Raise Radar Longevity Jobs New Companies on Longevity List 2021 Review: Quantifying the Longevity Industry My Links * Disclaimer : None of this should be taken as financial advice. It is for educational purposes only. Mission: To grow a wave of passionate people buildi … the Longevity Biotech startup ecosystem as a founder, early hire, or investor? Apply here . My longevity biotech rolling fund Healthspan Capital is now live on Angel List . We’ve raised our first quarter of capital, enlisted an amazing advisory board, and invested in three longevity startups so far. Our fund is uniquely public and accessible (min $5k) as to allow more sources of capital to enter the private longevity biotech industry. Sebastian Brunemeier (former Principal a … es. The reprogramming technique traces its roots back to Shinya Yamanka’s Nobel Prize winning work on induced pluripotency (2006) . Development of partial reprogramming is more recent, some notable examples: Ocampo / Belmonte’s in vivo partial reprogramming work in mice (2016) , and David Sinclair ’s reprogramming work demonstrating the regeneration of the optic nerve in mice (2019) . Epigenetic reprogramming is one of the most promising and perhaps overhyped approaches to re … ced that it had raised $100M in a Series C round led by Anthos Capital and SALT Fund . The funds will enable Cambrian to advance their existing programs and work with more scientific collaborators. Cambrian has 14+ programs under its umbrella, including assets from Sensei Biotherapeutics (phage cancer vaccine), Vita Therapeutics , and several others that have not been made public. The hub and spoke DisCo model consists of a parent holding company that holds stakes in daughter … Peyer. 🧬 Jean Hebert’s Brain Aging Reversal Tissue Engineering receives a $1M grant from The Methuselah Foundation. In early December, Jean Hebert , professor of neuroscience and genetics at Albert Einstein College of Medicine announced receipt of a $1M USD grant from the Methuselah Foundation to support his work on progressive replacement of n
Justin Briggs - Board of Directors — Morphoceuticals Justin Briggs, MBA Operating Partner at Prime Movers Lab Justin Briggs is Biologist and Operating Partner at Prime Movers Lab. He is a scientific entrepreneur and investor working at the nexus of biology, chemistry, and engineering. He supports portfolio company, Zafrens, full time and serves on the boards of Lygenesis and Iridia. Over the last 15 years, Justin was an operator at nearly a dozen biotech, nanotech, robotics, and software companies with multiple exits and over $100 million in venture backing. Justin also supported venture
Morphoceuticals Inc. Hails Successful Limb Regeneration in Adult Frogs using a Novel Drug Combination - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Morphoceuticals Inc. Hails Successful Limb Regeneration in Adult Frogs using a Novel Drug Combination January 27, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Morphoceuticals Inc. hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration … tion of functioning limbs, tissues, and organs. These findings herald the first application of a new of new set of tools that will be further developed by Morphoceuticals and will allow us to explore new approaches to regenerative treatment in ways that are truly unique". He added that "The potential applications are aimed at one day helping patients overcome the burden of loss of organs and limbs in ways that traditional medicine cannot,and that was why Juvenescence invested … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Morphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative Medicine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Morphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative Medicine February 15, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Morphoceuticals Inc., a biotechnology company, announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor J … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Media — Morphoceuticals Scroll 10.2024 To Reverse Aging’s Clock, Adjust the Cell’s Machinery GEN READ MORE Press Releases PRESENTATIONS | PUBLICATIONS | MEDIA 4. 18.24 Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology 2 .2023 Morphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative Medicine PRESENTATIONS | PUBLICATIONS | MEDIA | HOME Presentations PUBLICATIONS | MEDIA | PRESS RELEASES 9 .2023 Intelligence for Regenerative Medicine By Dr. Michael Levin 5 .2020 The Bioelectric Blueprints that Orchest
Industry – ION CHANNEL LIBRARY Skip to content Menu Find Partners Ion Channel World Map Companies Labs Nonprofits Resources Ion Channel Overview Fundamentals Ion Channel Drugs Interviews Analytics Expert opinions Books Infographics Journal Covers Quotes External Resources Blog Menu Find Partners Ion Channel World Map Companies Labs Nonprofits Resources Ion Channel Overview Fundamentals Ion Channel Drugs Interviews Analytics Expert opinions Books Infographics Journal Covers Quotes External Resources Blog Industry - 15/05/2023 Praxis Precision Medicines Announces Positive Topline Results f … ource: Maxion Therapeutics Industry - 07/02/2023 FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone Source: Sage Therapeutics Industry - 03/02/2023 Karuna Therapeutics to obtain global development, manufacturing, and commercialization rights to Goldfinch Bio’s investigational TRPC4/5 channel candidates. Source: Karuna Therapeutics Industry - 18/01/2023 Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its mar … Bionomics Industry - 15/12/2022 Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA Source: Vertex Industry - 14/12/2022 Praxis Precision Medicines partners with UCB to discover potential treatments for KCNT1-related epilepsies Source: Praxis Precision Medicines Industry - 14/12/2022 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 (ClC-1 inhibitor) for the Treatment … MDAR PAM) for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant Source: Aptinyx Industry - 04/11/2022 Saniona has finalized preclinical development of its KCa3.1 inhibitor SAN903 for the treatment of inflammatory and fibrotic diseases Source: Saniona Industry - 25/10/2022 Sophion Bioscience and Sussex Drug Discovery Centre strengthen collaboration Source: Sophion Bioscience Industry - 14/10/2022 Relmada Therapeutics reported a Phase III fail for its lead … ce: Relmada Therapeutics Industry - 12/10/2022 Muna Therapeutics receives $4.9M grant from the Michael J. Fox Foundation to support the development of Kv1.3 blockers for patients with Parkinson’s disease Source: Muna Therapeutics Industry - 12/10/2022 NMD Pharma Reports Positive Data from a Phase I/IIa Clinical Trial of its ClC-1 Chloride Ion Cha
Morphoceuticals Scroll Reprogramming the Software of Life Understanding and manipulating the bioelectrome to induce regeneration and treat disease. We are a TechBio company building the first atlas of the bioelectrome The bioelectrome is the set of communication networks within the body that bind multi-cellular collectives together for a common purpose, maintaining tissue and organ level integrity and health. It seamlessly connects the microscopic realm of individual cells to the vast complexity of the entire organism. By using multi-omics, bioelectric profiling and AI, we ca
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $39,261 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
Morphoceuticals Scroll Reprogramming the Software of Life Understanding and manipulating the bioelectrome to induce regeneration and treat disease. We are a TechBio company building the first atlas of the bioelectrome The bioelectrome is the set of communication networks within the body that bind multi-cellular collectives together for a common purpose, maintaining tissue and organ level integrity and health. It seamlessly connects the microscopic realm of individual cells to the vast complexity of the entire organism. By using multi-omics, bioelectric profiling and AI, we ca
News – ION CHANNEL LIBRARY Skip to content Menu Find Partners Ion Channel World Map Companies Labs Nonprofits Resources Ion Channel Overview Fundamentals Ion Channel Drugs Interviews Analytics Expert opinions Books Infographics Journal Covers Quotes External Resources Blog Menu Find Partners Ion Channel World Map Companies Labs Nonprofits Resources Ion Channel Overview Fundamentals Ion Channel Drugs Interviews Analytics Expert opinions Books Infographics Journal Covers Quotes External Resources Blog Industry - 15/05/2023 Praxis Precision Medicines Announces Positive Topline Results from … ource: Maxion Therapeutics Industry - 07/02/2023 FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone Source: Sage Therapeutics Industry - 03/02/2023 Karuna Therapeutics to obtain global development, manufacturing, and commercialization rights to Goldfinch Bio’s investigational TRPC4/5 channel candidates. Source: Karuna Therapeutics Research - 28/01/2023 Mechanical forces caused by foetal movements drive skeletal development Source: University C … apy for ALS Source: QurAlis Research - 24/12/2022 Treating gut pain via a Nobel prize-winning receptor Source: Flinders University Industry - 21/12/2022 Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd Source: Catalyst Pharmaceuticals Industry - 21/12/2022 Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments Source: PRNewswire Industry - 20/12/2022 Sionna Therapeutics Announces IN … Bionomics Industry - 15/12/2022 Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA Source: Vertex Industry - 14/12/2022 Praxis Precision Medicines partners with UCB to discover potential treatments for KCNT1-related epilepsies Source: Praxis Precision Medicines Industry - 14/12/2022 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 (ClC-1 inhibitor) for the Treatment … MDAR PAM) for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant Source: Aptinyx Industry - 04/11/2022 Saniona has finalized preclinical development of its KCa3.1 inhibitor SAN903 for the treatment of inflammatory and fibrotic diseases Source: Saniona Research - 03/11/2022 Extracellular fluid viscosity enhances cell migration
Biotech Opportunities | Department of Biology Skip to main content Department of Biology Tufts Center for Regenerative and Developmental Biology SCHOOL OF ARTS AND SCIENCES Open search Close search Open menu Close menu Tufts Center for Regenerative and Developmental Biology About Contact Us Publicity Biotech Opportunities Publications Presentations People Seminars Department of Biology SCHOOL OF ARTS AND SCIENCES Biotech Opportunities Overview A number of our projects suggest ready applications as exciting advances in biomedicine . This page is constantly being updated with new informati … e Program: BS/MS in Biology MS in Biology PhD in Biology Undergraduate Students Apply Request Info Visit Graduate Students Apply Request Info Visit Contact Department of Biology has two locations: 200 College Ave. Medford, MA 02155 Map and Directions Tel: 617-627-2264 Fax: 617-627-3805 200 Boston Ave. Medford, MA 02155 Map and Directions Tel: 617-627-3539 Fax: 617-627-3805 Email Department twitter linkedin © Tufts University 2026 Non-Discrimination Statement Privacy Tuft
Tufts Annual Inventor Recognition Event FY2023 | Tufts Office of the Vice Provost for Research Skip to main content Menu Office of the Vice Provost for Research Menu About Vice Provost for Research Leadership OVPR Staff Functions & Programs Information & Resources Initiatives Internal Seed Funding TRACC Services Research Lifecycle Support Functions & Programs Core Facilities & Resources Policies, Forms & Guides Trainings News & Events News Events Announcements Annual Reports Collaborate Find Collaborators Meaningful relationships are the foundation of successful, interd … eds to perform a task in response to an instruction from a human instructor, to apply the acquired knowledge, and to instruct other intelligent systems about the relevant knowledge for performing the task. Igor Sokolov 11,506,683 Atomic-force microscopy for identification of surfaces A method using an atomic-force microscope to acquire a set of images associated with cell surfaces and applying a machine-learning algorithm to the images to classify such cells as cancerous, or … amp; Programs Search OVPR Staff More Ways to Connect Subscribe to Announcements Submit News & Events Website Support General Feedback @TuftsOVPR Footer Fourth Column Technology Commercialization Corporate Partnerships See Announcements See Upcoming Events See Featured Research
Morphoceuticals - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Ban
Michael Levin, PhD - Scientific Co-Founder — Morphoceuticals Michael Levin, PhD Scientific Co-Founder Michael Levin, PhD, is a Scientific co-founder and Advisor of Morphoceuticals. He has more than 25 years of experience in biology research, during which he identified the first genetic pathway that determines the left-right asymmetry of body organs. Michael is founding director of the Allen Discovery Center at Tufts University, and is Vannevar Bush Distinguished Professor, with an associate appointment at Harvard's Wyss Institute . His lab uses a range of computational and biophysics app
Jim Jenson - Board of Directors — Morphoceuticals Jim Jenson, PhD CEO, Morphoceuticals Jim Jenson, PhD, is the Chief Executive Officer at Morphoceuticals. He has more than 35 years of experience in the biotech and pharmaceutical industries, as both an entrepreneur and executive leader. He most recently served as the Co-founder and CEO of CytoSite Biopharma Inc., which develops new technology to predict and monitor responses to immuno-oncology therapy. Jim was CEO and Co-founder of Dicerna Pharmaceuticals, Inc., a developer of RNAi based therapeutics, which Novo Nordisk acquired in 2021 f
Morphoceuticals - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to s
2-15-23 — Morphoceuticals 2.15.23 Morphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative Medicine BOSTON, Feb. 15, 2023 /PRNewswire/ -- Morphoceuticals Inc. , a biotechnology company, announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence. Morphoceuticals is pioneering the use of artificial intelligence-guided electroceuticals to regenerate limbs, repair tissues, and regenerate organs, leveraging the groundbreaking work of Professors Michael Levin and David Kaplan from Tufts University. Morphoc
Leadership — Morphoceuticals Scroll Leadership Jim Jenson, PhD CEO Michael Levin, PhD Scientific Co-Founder David Kaplan, PhD Scientific Co-Founder Nicolas Palacios-Prado, PhD Director of Technology Development Meisam Bagheri, PhD Scientist Cathal McLoughlin, PhD Scientist Melissa Brown-Davis, PhD Associate Scientist Board of Directors Dr. Roger J. Pomerantz Chairman Jim Jenson, PhD CEO, Morphoceuticals Alexander Pickett Managing Director, Juvenescence Justin Briggs, MBA Operating Partner, Prime Movers Lab Tamim Hamad J.J. Al-Thani Michael Hufford, PhD CEO, Ly
Form D FORM D Notice of Exempt Offering of Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. OMB APPROVAL OMB Number: 3235-0076 Estimated Average burden hours per response: 4.0 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) None Entity Type 0001962989 Corporation Limited Partnership Limited Liability Company General Partnership Business Trust Other Name of Issuer Morphoceuticals, Inc. Jurisdiction of Incorporation/Organization DELAWARE Year of Incorporation/Organization Over Five Years Ago Within Last Five Years (Specify Year) 2020 Yet to Be Formed 2. Pr … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate Retailing Restaurants Tech … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 506(b) Rule 504 (b)(1)(i) Rule 506(c) Rule 504 (b)(1)(ii) Securities Act Section 4(a)(5) Rule 504 (b)(1)(iii) Investment Company Act Section 3(c) 7. Type of Filing New Notice Date of First Sale 2023-01-13 First Sale Yet to Occur Amendment 8. Duration of Offering Does the Issuer intend this offering to last more than one year? Yes No 9. Type(s) of … st more than one year? Yes No 9. Type(s) of Securities Offered (select all that apply) Pooled Investment Fund Interests Equity Tenant-in-Common Securities Debt Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, such … ve entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission In submitting this notice, each Issuer named above is: Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request
Morphoceuticals, Inc. Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Morphoceuticals, Inc. Morphoceuticals, Inc. Marblehead, MA Watchlist Export About Financials People Deals Funding About Morphoceuticals, Inc. Company overview Morphoceuticals, Inc. is a privately-held biotech firm intended for limb regeneration and the discovery of novel regenerative interventions. Morphoceuticals, Inc. was founded in 2020 by David Kaplan and Michael Levin. Morphoceuticals, Inc. headquarters are located in Marblehead, Massachusetts. Keywords Revenue Revenue EBIT
Jim Jenson, PhD - CEO — Morphoceuticals Jim Jenson, PhD Chief Executive Officer Jim Jenson, PhD, is the Chief Executive Officer at Morphoceuticals. He has more than 35 years of experience in the biotech and pharmaceutical industries, as both an entrepreneur and executive leader. He most recently served as the Co-founder and CEO of CytoSite Biopharma Inc., which develops new technology to predict and monitor responses to immuno-oncology therapy. Jim was CEO and Co-founder of Dicerna Pharmaceuticals, Inc., a developer of RNAi based therapeutics, which Novo Nordisk acquired in 2021 for $3.3
Morphoceuticals Scroll Reprogramming the Software of Life Understanding and manipulating the bioelectrome to induce regeneration and treat disease. We are a TechBio company building the first atlas of the bioelectrome The bioelectrome is the set of communication networks within the body that bind multi-cellular collectives together for a common purpose, maintaining tissue and organ level integrity and health. It seamlessly connects the microscopic realm of individual cells to the vast complexity of the entire organism. By using multi-omics, bioelectric profiling and AI, we ca
Juvenescence Ltd. Portfolio Company Hails Successful Limb Regeneration in Adult Frogs | Business Wire Sök nyheter Abonnera Sök pressrum Om tjänsten Bli kund Juvenescence Ltd. Portfolio Company Hails Successful Limb Regeneration in Adult Frogs 31.1.2022 06:00:00 CET | Business Wire | Press Release Share Morphoceuticals Inc., a portfolio company of Juvenescence Ltd., hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration of limbs in Xenopus laevis (African clawed frog). This is the first demonstration of functional limb regenerat … tion of functioning limbs, tissues, and organs. These findings herald the first application of a new set of tools that will be further developed by Morphoceuticals and will allow us to explore new approaches to regenerative treatment in ways that are truly unique.” He added that, “The potential applications are aimed at one day helping patients overcome the burden of loss of organs and limbs in ways that traditional medicine cannot, and that was why Juvenescence invested and … completed a second closing of its Series B round. The transaction brings in EIC Fund with a private investor who will support the company’s next phase of growth and increases H2SITE’s total funding raised in this round to more than €42 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624444396/en/ H2SITE These new partners, join BEV, Suma Capital, Hy24, Crane, Enagás Emprende, Calderion and CRPV who parti … surance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klar Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project 24.6.2026 16:00:00 CEST | Press Release Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base
PRESS RELEASE: April 18, 2024 – Morphoceuticals Names Jim Jenson, PhD as CEO — Morphoceuticals 4.18.24 Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology Company seeks to build the first map of the druggable bioelectrome BOSTON, Apr. 18, 2024 – MEDFORD, MA. – Morphoceuticals Inc. , a new biotechnology company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO. Jenson joins a growing team and will lead the company as it adv
A new treatment helped frogs regenerate their amputated legs – taking science one step closer to helping people regrow their body parts, too Search analysis, research, academics… Home Edition Africa Australia Brasil Canada Canada (français) Català España Europe France Global Indonesia New Zealand United Kingdom United States Skip to content Edition: Europe Africa Australia Brasil Canada Canada (français) Català España France Global Indonesia New Zealand United Kingdom United States s Newsletters Academic rigour, journalistic flair Reactivating the signals cells use to regenerate could help pat
Taming the Collective Intelligence of Cells for Regenerative Medicine - Foresight Institute Menu Focus Areas Secure AI Neurotechnology Longevity Biotechnology Nanotechnology Space Existential Hope Engage Vision Weekend Workshops AI Nodes Grants Prizes Fellowship Seminar Groups Resources Recordings Podcasts Reports Book: Gaming the Future About Donate Focus Areas Secure AI Neurotechnology Longevity Biotechnology Nanotechnology Space Existential Hope Engage Vision Weekend Workshops AI Nodes Grants Prizes Fellowship Seminar Groups Resources Recordings Podcasts Reports Book: Gaming the Future Abou … rative and Developmental Biology. Recent honors include the Scientist of Vision award and the Distinguished Scholar Award. His group’s focus is on understanding the biophysical mechanisms that implement … Read More Presentation: Michael Levin Transformative medicine will address aging and many other things, which is why regenerative medicine is so important. If I had to boil down the talk to one sentence, this would be it – all of your body cells and tissues make decisions ab … the electrical information processing in the tissue. We do not use electrodes, apply electric fields, no electromagnetics. This is purely molecular physiology that targets the native processes by which these cells are communicating electrically. There are ways to control the topology of the network – which cells talk to which other cells. We can open and close gap junctions and so on, and the same for ion channels – we can go in and set the states using either optogenics or … technologies give you the cleanest pathway information, but I think in medical application you don’t want to have to do gene therapy every time you want to target these pathways. And you don’t have to. We’ve had great success using the drugs together with a computational model – that’s the key, you need both. Arsenal of available ion channel drugs and the model to tell you which channels to turn on and off and when to get the correct outcome. Is there a relationship between … essed with your in vivo results with frog limb regeneration. Regarding in vitro application, can your drug cocktails or similar interventions be used for suspension culture to grow some vascularized organoids, or vascularized muscle tissues for clean meat application, or for in vitro you have to do something different? I think they absolutely can
Senior Scientist, Neuroelectrophysiology Salary Data & Market Analysis | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support Senior Scientist, Neuroelectrophysiology H-1B & Green Card Salary Data and Market Analysis Search for another profession Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only Experience Level All Levels Unspecified Entry Level Junior Mid Level Senior Staff Principal Lead Manager Director 1 Total
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account July 22, 2025 07:00 ET | Source: Morphoceuticals, Inc. Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors Morphoceuticals announces the appointment of industry veteran Roger Pomerantz, MD, as Chairman of its Board of Directors.
Morphoceuticals Inc. Hails Successful Limb Regeneration in Adult Frogs using a Novel Drug Combination Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia A … tion of functioning limbs, tissues, and organs. These findings herald the first application of a new of new set of tools that will be further developed by Morphoceuticals and will allow us to explore new approaches to regenerative treatment in ways that are truly unique". He added that "The potential applications are aimed at one day helping patients overcome the burden of loss of organs and limbs in ways that traditional medicine cannot,and that was why Juvenescence invested … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Privacy Policy — Morphoceuticals Privacy Policy Effective Date: April 4, 2024 Morphoceuticals, Inc. (“Morphoceuticals,” “we,” “us,” “our”) is committed to respecting the privacy of visitors to our website (“you”). This Privacy Notice explains what personal data we collect about you, how we collect that personal data, for what purposes we use such personal data, to whom we disclose such personal data, and how you can limit our use of your personal data. Morphoceuticals is the data controller of personal data we collect through our website. Please read this Privacy Notice carefully before … t you voluntarily provide to us, such as when you contact us via our website to apply for a job, submit an inquiry, or otherwise attempt to contact us. If you refuse to provide your personal data in connection with such a request, it may affect the quality of our services, but you should still be able to use basic functions of services delivered by this website. We typically receive minimal personal data from individuals who contact us via our website for the above purposes, … , we will use such information only as described in this Privacy Notice. If you submit personal data relating to other people to us, you represent that you have the authority to do so and to permit us to use that personal data in accordance with this Privacy Notice. Cookies & Other Tracking Technologies We use cookies and other tracking technologies on our website to operate our site and to conduct marketing and analytics. Further, certain web browsers and other programs
Morphoceuticals | The Org Platform Enrich Pricing Log in Sign up Morphoceuticals 0 followers Morphoceuticals Inc. is a biotechnology company co-founded by Drs. Levin and Kaplan and funded by Juvenescence Ltd. Morphoceuticals is pioneering bioelectric approaches to access anatomical programming that is a core component of our biological operating system. Using proprietary combinations of ion... Read more Industries Biotechnology , Research Headquarters Boston, United States Employees 1-10 Links Org chart Teams Offices Positions ( 11 ) Unverified Org chart Jacqueline Jeha Interim Director of C
SEC FORM D The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001. FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00 1. Issuer's Identity CIK (Filer ID Number) Previ … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(4) Section 3(c)(12) Section 3(c)(5) Section 3(c)(13) Section 3(c)(6) Section 3(c)(14) Sec … more than one year? Yes X No 9. Type(s) of Securities Offered (select all that apply) X Equity Pooled Investment Fund Interests Debt Tenant-in-Common Securities Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, su … tate/Province/Country ZIP/Postal Code State(s) of Solicitation (select all that apply) Check “All States” or check individual States All States Foreign/non-US 13. Offering and Sales Amounts Total Offering Amount $ 9,820,000 USD or Indefinite Total Amount Sold $ 9,820,000 USD Total Remaining to be Sold $ 0 USD or Indefinite Clarification of Respon
The Levin Lab: Home The Levin Lab Home Research Overview Temporal Information Spatial Information Lab's New Directions Mind Maps Publications Peer-Reviewed Papers Editorials Preprints Popular Press Presentations Talks Audio & Video Interviews Print Interviews People Principal Investigator Lab Members Photo Galleries Resources Frequently Asked Questions Course Materials Conferences and Symposia Conversations and Guests Tools and Software Image Gallery Additional Affiliations Other Labs of Interest Inspiration Jobs Overview Contact Us Overview About the Lab Students Overview Awards Papers Pu
Morphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative Medicine Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Phot … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Morphoceuticals Inc - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> Morphoceuticals Inc Bioelectric control of regeneration Website Profile prev next Website Bookmark Share prev next General Headquarters Road Town, British Virgin Islands Founders & Team Michael Levin, David Kaplan Year Founded 2020 Company type Private company Investors Juvenescence Technical Details Aging Target Cell Loss About This developing tech
Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and G … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology April 18, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Morphoceuticals Inc. announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO. Jenson joins a growing team and will lead the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Dr. Roger J. Pomerantz, Chairman — Morphoceuticals Dr. Roger J. Pomerantz Chairman Dr. Roger J. Pomerantz has a biomedical career that spans key senior leadership positions in academic medicine, small and large biopharmaceutical organizations, global therapeutic franchises, and business development, licensing, and acquisitions at world-wide pharmaceutical companies. He has led the development of 14 large and small molecule therapies for HIV, HCV, MDR-TB, CMV, and C Diff, which have been approved and launched globally. He was the President, CEO and Chairman of Seres Therapeutics, the firs … s Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School, and was selected and served as the Chief Medical Resident at Massachusetts General Hospital. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Wh
PRESS RELEASE: Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors — Morphoceuticals 7.22.25 Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors July 22, 2025 – Medford, MA. – Morphoceuticals Inc. , a TechBio company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of industry veteran Roger Pomerantz, MD, as Chairman of its Board of Directors. Pomerantz joins as an independent director. The company is advancing a novel technology platform, based on the fi
Search - RealDealDocs Skip to content Search Browse Categories Latest Docs Clauses Pricing Blog Join Account Login Toggle Menu Account Search Search Tips Double Quotes for: " Exact Term Match " Minus for Must Not Contain: – Negative If you search for a document title (with or without quotes), you will see documents that match that title first and then other results. If you search for that title in double quotes it will only show results with that exact phrase with title matches first. You can add additional queries like this "exact phrase" keyword -negativeword This will look for t … You can filter keyword results on the results page or use Advanced Filters and submit below. All Agreements Account Control Agreement Accounting Agreement Administrative Agreement Advisory Agreement Agency Agreement Arbitration Agreement Articles of Incorporation Asset Exchange Agreement Assignment Agreement Assumption Agreement Award Agreement Bridge Loan Agreement Broker Agreement Business Combination Agreement Call Option Agreement Cash Management Agreement Change In Cont … earance Agreement Framework Agreement Franchise Agreement Fuel Supply Agreement Fund Manager Agreement Funding Agreement Gas Agreement Gas Marketing Agreement Guaranty Agreement Hedge Agreement Hosting Agreement Indemnification Agreement Indenture Industrial Lease Insurance Agreement Intellectual Property Agreement Intercreditor Agreement Invention Assignment Agreement Investment Agreement Investment Management Trust Agreement Irrevocable Trust Agreement Joinder Agreement Joi … Agreement Patent Assignment Agreement Patent License Agreement Performance Unit Award Agreement Placement Agent Agreement Placement Agreement Pledge Agreement Power Agreement Power Of Attorney Press Release Private Shelf Agreement Production Agreement Profit Sharing Plan Promissory Note Promotion Agreement Proxy Agreement Purchase Agreement Purchase And Sale Agreement Put Option Agreement Recapitalization Agreement Receivables Agreement Redemption Agreement Reimbursement Agre … ssor Bell & Peskoe LLP Goodmans LLP Goodwin Procter LLP Goodwin Proctor LLP Grant Thornton LLP Graubard Miller LLP Gray Reed LLP Greenberg Glusker LLP Greenberg Traurig LLP Greenburg Traurig LLP Greg Kramer Esq Gregg A. Noel Esq Gregory P. Patti Jr. Esq Gregory Sichenzia Esq Gregory W. Gribben Esq Griffin Partners LLP Gross Esq GSK PLC Guaran
BusinessWire News Feed - HealthTech HotSpot Skip to content LinkedIn X Facebook YouTube About Contact Us Editorial Guidelines Hot HealthTech News, Views and Trends Search for: Home Home Digital Health Health AI Healthcare IT Medical Imaging More HealthTech Events HIMSS 2026 HLTH 2025 RSNA 2025 SUBSCRIBE Search for: Home Home Digital Health Health AI Healthcare IT Medical Imaging More HealthTech Events HIMSS 2026 HLTH 2025 RSNA 2025 SUBSCRIBE Home Home Digital Health Health AI Healthcare IT Medical Imaging More HealthTech Events HIMSS 2026 HLTH 2025 RSNA 2025 SUBSCRIBE Search for: BusinessWire … specialist, and employee benefits specialist, has been honored with the Silver Award for Best HR Management System at the Human Resources Online HR more... VSAVA and NEL Animal Medical Foundation Partner to Introduce Vietnam’s First Specialized Veterinary Cardiology Course November 5th, 2025 | A gateway for cooperation to advance Asian veterinary medicine Exchange of expertise in internal medicine, diagnostic imaging, and practical training with participation from Viet … h Day 24th June 2026 AngelEye Health’s Katie Taylor Named 2026 Parents Next Gen Award Winner 24th June 2026 New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life’s Setbacks 24th June 2026 AIHA Announces New 2026-2027 Board Members, Prepares for Inaugural Strategic Meeting in Houston, TX 24th June 2026 LivaNova to Announce Second-Quarter 2026 Results 24th June 2026 Please leave this field empty Subscribe to Our Newsletter Check your inbox or sp
Aging Companies site: intro & high level: why & feasibility: orgs & ecosystem: keeping up: connecting: available now: how to help: resources: Home Books Motivations Companies Blogs/News Conferences Therapeutics Jobs Databases About Documentaries Objections InvestorsXCompanies Journals Forums Diagnostics Opportunities Contact Categories Convincers Trials Podcasts People Nonprofits Videos If the interactive (sortable, etc.) version of the table above doesn't work, you can view the static HTML version .
Faculty in the News - 2022-2023 | School of Arts and Sciences Skip to main content Skip to search School of Arts and Sciences Information for Current Students Prospective Undergraduate Students Prospective Graduate Students Faculty Staff Alumni Find Faculty Apply Give Open search Close search Open menu Close menu About Leadership 2026 Strategic Plan Annual Reports Inclusive Excellence Working in Arts and Sciences Jumbo Appreciation Awards Contact Us Academics Departments and Interdisciplinary Programs Academic Centers and Resources Undergraduate Studies Graduate School of Arts and Sciences SMF … aduate Students Prospective Graduate Students Faculty Staff Alumni Find Faculty Apply Give Breadcrumb Home Faculty & Research Faculty In The News Faculty In The News - 2022-2023 Faculty in the News - 2022-2023 Summer 2023 10 million enslaved Americans' names are missing from history. AI is helping identify them. August 31, 2023 National Geographic Associate Professor of History Kendra Field is quoted throughout this article on the newly launched 10 Millio … Policy & Planning Mark Chase is quoted regarding Somerville City Council's proposal to de-prioritize police enforcement against cyclists who travel through red lights is included in this article. Colonization Was the ‘Luckiest Thing’ to Happen to Australia, Ex-Leader Says July 26, 2023 The New York Times Chair of the Department of Studies in Race, Colonialism, and Diaspora Kris Manjapra is quoted about recent commentary in the media that suggests historical at … iting in predominantly minority schools and areas. How to Write Music for Rolling Boulders July 7, 2023 The New York Times With the aid of embedded music clips, Associate Professor of Music Frank Lehman examines pieces from composer John Williams’ “Indiana Jones” series to make the case that “while effective action music sets the filmgoer on edge, truly great action music can stand on its own.” Poet Sara Deniz Akant Talks Uncertainty, Turkish Identity, … discussion of books on the short list for the 2023 National Book Critics Circle award for biography. Deleting a Gene Quells a Pesky Cheese-destroying Fungus June 30, 2023 The Scientist This article highlights new research from Associate Professor of Biology Benjamin Wolfe who used cheese rinds to examine the role of fungi and its inter
false 2025 FY 0001095435 0001095435 2024-04-01 2025-03-31 0001095435 dei:BusinessContactMember 2024-04-01 2025-03-31 0001095435 2025-07-21 0001095435 2025-03-31 0001095435 2024-03-31 0001095435 2023-04-01 2024-03-31 0001095435 2022-04-01 2023-03-31 0001095435 ifrs-full:IssuedCapitalMember 2022-03-31 0001095435 ptgef:StockOptionReserveMember 2022-03-31 0001095435 ptgef:AccumulatedOtherComprehensiveIncomeLossMember 2022-03-31 0001095435 ifrs-full:RetainedEarningsMember 2022-03-31 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-03-31 0001095435 ifrs-full:NoncontrollingInterests … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of " large accelerated filer,” large accelerated filer," and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ &# … financial performance in the event that we were to raise additional capital to fund the clinical development of our programs.   Risks Related to our Business   We have current and future capital needs, and there are uncertainties as to our ability to raise additional funding.   Our current cash resources will not cover all of our operational costs and the needs of our subsidiaries to progress towards and carry our clinical trials. Additional capital would be n … ngs have been from related parties, none of whom have any obligation to further fund the company.  We believe we will have to raise substantial amounts of additional capital from time to time, including in the near future, to continue our operations and to fund any of our product development, to conduct clinical trials, to obtain regulatory approval, to safeguard our intellectual property, and to commence any commercialization efforts that we may pursue in the future. To … ining patent protection or patent licenses can be costly and the outcome of any application for patent protection and patent licenses can be unpredictable. In addition, any breach of confidentiality by a third party by premature disclosure may preclude us from obtaining appropriate patent protection, thereby affecting the development and commerci
Member Benefits - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link Align Summit Partneri … Programs and initiatives for members to source, accelerate, collaborate on, and fund groundbreaking innovations. Workforce Development : MassBio is dedicated to ensuring a workforce pipeline that fits the needs of our member companies. Visibility Opportunities Events & Networking | Professional development and networking events with our premier conferences, forums, roundtables, and mixers. Sponsorship Opportunities | Sponsor a MassBio event and set your company apart whil … ing with the leading life sciences cluster of the world. Community Engagement | Submit thought leadership blogs, post news, and list events on the MassBio website and LinkedIn Virtual Community page. Become a member today! Be a part of an unparalleled network of innovative companies & industry thought leaders. Join now Member Spotlight Member Spotlight: Symmetric Computing, Inc. June 8, 2026 The research and development at Symmetric Computing has resulted in both a US pat … resulted in both a US patent for a new computer architecture and an innovation award from NIH…. Member Spotlight: Intersect™ at Triple Ring May 18, 2026 Triple Ring Technologies is a corporate growth lab headquartered in Silicon Valley, with offices in Boston, Toronto, and Copenhagen. We partner with clients in medtech,… Member Spotlight: Kerry Murphy Healey Center for Health Innovation and Entrepreneurship at Babson College May 11, 2026 The Kerry Murphy Healey C
Medical Scientists, Except Epidemiologists Salaries — H-1B & PERM Database U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support Medical Scientists, Except Epidemiologists salaries 2,494 H-1B & PERM records for "Medical Scientists, Except Epidemiologists", sourced from U.S. Department of Labor disclosures. Looking for green-card wait times instead? See EB-1, EB-2 & EB-3 priority dates by country . Search H-1B & Green Card Salary Data Source: US Dept of Labor. Represents Base Salary only
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Drug Development Archives - Page 15 of 24 - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder
Member Spotlight: Morphoceuticals, Inc. - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Li
Morphoceuticals, Inc. H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support Morphoceuticals, Inc. H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 1 Total Filings 2021-Present 100.0% App